Clinical Trial:

Phase I Study of the Novel Antifolate Pralatrexate in Combination with the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients with Relapsed and Refractory Lymphoid Malignancies

This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, we'll continue the study, but only accrue patients with peripheral T-Cell lymphoma (PTCL). Pralatrexate and Romidepsin will be given on day 1 of each 28-day cycle.